Abecma (idecabtagene vicleucel) — HCPCS Q2055

About Abecma (idecabtagene vicleucel)

Abecma is the brand name for idecabtagene vicleucel (ide-cel), an autologous chimeric antigen receptor (CAR) T-cell immunotherapy directed against the B-cell maturation antigen (BCMA), co-developed by Bristol-Myers Squibb (via Celgene) and 2seventy bio (formerly bluebird bio's oncology spinout). This is NOT a CD19 CAR-T — it targets BCMA, expressed on plasma cells and myeloma cells, and is approved exclusively for multiple myeloma. Abecma was the first CAR-T cellular therapy ever approved for multiple myeloma (March 26, 2021), preceding Carvykti by approximately 11 months, and the first BCMA-directed therapeutic of any class to reach FDA approval. That historical role matters operationally: most early CAR-T centers built their BCMA workflow, REMS infrastructure, and payer policy templates around Abecma before Carvykti existed.

Each Abecma dose is a patient-specific cellular product built on a conventional single BCMA-binding-domain construct: an scFv-based CAR targeting one epitope on the BCMA molecule, mounted on a 4-1BB costimulatory domain. This is the architectural baseline against which Carvykti's later dual-VHH construct is compared. The single-domain design produces predictable, well-characterized pharmacology and a CRS/ICANS profile that closely resembles CD19 CAR-T products — without the delayed Parkinsonism / movement and neurocognitive toxicity (MNT) signal that distinguishes Carvykti. The patient's T cells are collected by leukapheresis, shipped to the BMS / 2seventy bio manufacturing facility, genetically modified to express the BCMA CAR, expanded, cryopreserved, and shipped back to the certified treatment center. Abecma's vein-to-vein time is approximately 4-6 weeks, somewhat faster than Carvykti's 5-7 weeks — an operational consideration for rapidly progressing myeloma.

Abecma carries two FDA-approved indications:

• Adult relapsed/refractory multiple myeloma (4L+) after at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody — approved March 26, 2021 based on the KarMMa trial (Munshi NC et al., NEJM 2021). This was the FIRST CAR-T approval in multiple myeloma of any kind.
• Adult relapsed/refractory multiple myeloma (2L+) after at least two prior lines of therapy including an IMiD, a proteasome inhibitor, and an anti-CD38 monoclonal antibody (triple-class exposed) — approved April 4, 2024 based on the KarMMa-3 trial (Rodriguez-Otero P et al., NEJM 2023). This was a parallel approval to Carvykti's CARTITUDE-4 (which came one day later on April 5, 2024), and brought BCMA CAR-T into the 2L+ setting in multiple myeloma.

Abecma is billed under HCPCS Q2055 as a single therapeutic dose. The HCPCS descriptor explicitly identifies the BCMA target (distinguishing Q2055 from the CD19 CAR-T Q-codes Q2041, Q2042, Q2053, Q2054). Administration is restricted to FACT-accredited centers certified under the ABECMA REMS program, which is independently administered by BMS through BMS Cell Therapy 360 (separate from the Janssen Carvykti REMS, even though both products are BCMA CAR-T). Approximate list price (single dose): ~$465,000 USD.

BCMA cellular therapy class — Abecma vs Carvykti vs Tecvayli vs Elrexfio FDA + payer review May 2026

Two BCMA-directed CAR-T products plus two BCMA bispecifics are approved for R/R multiple myeloma. Coding and PA logic are not interchangeable. Abecma is NOT a CD19 CAR-T.

The 5-stage CAR-T workflow FDA label + REMS verified May 2026

Abecma billing is fundamentally different from standard drug billing because the encounter spans 6-10 weeks across multiple claims. Unlike Carvykti, there is no extended ≥1-year neurological surveillance tail.

Typical claim cadence

1. Claim A — Apheresis encounter: CMS-1500 or UB-04 with 38206 (or 0540T) + supporting ICD-10 (C90.0x active myeloma). Often paid as outpatient hospital service or office procedure.
2. Claim B — Lymphodepletion encounter(s): J9185 + J9070 with admin CPTs 96413/96415 as appropriate. May span 3 outpatient visits or one short admission.
3. Claim C — CAR-T admission: UB-04 inpatient with ICD-10-PCS procedure (XW033C3 or XW043C3) driving MS-DRG 018. Q2055 line-item is included in the DRG bundle. Or, in outpatient infusion path, UB-04 outpatient with APC payment + Q2055 + 0537T-0541T line items.
4. Claim D — CRS/ICANS readmission (if applicable): Inpatient DRG based on principal manifestation (sepsis, respiratory failure, encephalopathy) with tocilizumab and supportive care billed within the DRG.

Dosing & cellular dose math FDA label verified May 2026

Abecma is one therapeutic dose, a flat-range cellular product targeting 150-450 x 10^6 CAR-positive viable T cells. The HCPCS descriptor permits up to 510 x 10^6 cells per dose. Dose is NOT weight-based.

Lymphodepletion dosing (Stage 3) — uniform across indications

Per the FDA Abecma label, the lymphodepletion regimen is the same regardless of indication: fludarabine 30 mg/m^2 IV daily x 3 days (J9185) plus cyclophosphamide 300 mg/m^2 IV daily x 3 days (J9070), days -5 to -3. CAR-T cell infusion proceeds on day 0 (2 days after the last lymphodepletion dose). This is the same cyclophosphamide dose used for Carvykti and Breyanzi (300 mg/m^2), not the higher 500 mg/m^2 used with Yescarta and Tecartus MCL.

NDC reference FDA NDC Directory + BMS verified May 2026

Abecma uses a patient-specific NDC pattern - every patient's dose is uniquely identified by lot under the BMS/Celgene labeler family. BMS Cell Therapy 360 supplies labeler documentation directly.

ABECMA REMS + FACT accreditation BMS + FACT verified May 2026

Abecma is available only through a restricted REMS program because of the boxed warnings for CRS, ICANS, HLH/MAS, prolonged cytopenias, and secondary hematological malignancies (including T-cell malignancies per the FDA class-wide CAR-T update).

The ABECMA REMS is administered by Bristol-Myers Squibb through BMS Cell Therapy 360 and operates as closed distribution. Three certification layers must all be in place — and although Abecma and Breyanzi share the BMS Cell Therapy 360 hub, REMS certifications remain product-specific:

• Facility certification (BMS Authorized Treatment Center): the hospital or cellular therapy center must be on the BMS-maintained list of authorized Abecma Treatment Centers. Certification requires FACT or FACT-JACIE accreditation for cellular therapy, demonstrated capacity to recognize and manage CRS and ICANS, immediate availability of tocilizumab (Actemra) for IV use, and qualified ICU backup. Unlike CARVYKTI REMS, the ABECMA REMS does NOT require a separate Parkinsonism/MNT neurological monitoring infrastructure — Abecma does not carry that delayed-toxicity signal.
• Healthcare provider certification: prescribing physicians must complete the ABECMA REMS training and be enrolled. The training covers CRS, ICANS, HLH, and prolonged cytopenia management but does not include the Carvykti-specific MNT module.
• Pharmacy / chain-of-custody certification: the receiving pharmacy and cellular therapy lab must verify physician + facility certification before accepting the patient-specific cellular product.

How to enroll / verify

• Web: BMS maintains the ABECMA REMS portal — check the most recent Abecma Prescribing Information for the current REMS URL and contact. BMS Cell Therapy 360 (the joint Abecma + Breyanzi patient hub) can route facility questions to the REMS team.
• FACT accreditation: factwebsite.org — verify accreditation status of any center before referral.
• Documentation: retain REMS enrollment confirmation in the patient chart and on every PA submission. Submit FACT accreditation certificate as a PA attachment. Document indication-specific eligibility (triple-class exposure for KarMMa-3 2L+, or PI + IMiD + anti-CD38 for KarMMa 4L+) in the PA narrative.

Administration codes — the multi-stage code set CPT 2026 verified May 2026

Each of the 5 stages has its own administration code family. Map them to the correct claim.

Stage 1 - Apheresis

Stage 3 - Lymphodepletion (chemo admin)

Stage 4 - CAR-T infusion administration set

Stage 5 - CRS / ICANS management

Tocilizumab (Actemra, HCPCS J3262) is the FDA-approved CRS treatment. Dose for CRS: 8 mg/kg IV (max 800 mg), up to 4 doses. Bill J3262 with appropriate IV infusion admin code (96365). When CRS occurs during the inpatient CAR-T admission, tocilizumab is bundled in MS-DRG 018; when administered outpatient or during a separate readmission, bill J3262 line-item against the relevant ICD-10 (D89.83x for CRS).

Abecma vs Carvykti monitoring window: Standard 30-day post-infusion monitoring applies for Abecma; the CRS and ICANS profiles are well-characterized and align with CD19 CAR-T products in time-course. Abecma does NOT require the extended baseline + serial Parkinsonism/MNT neurological assessments through ≥ 1 year post-infusion that the CARVYKTI REMS mandates. This is a structural operational difference between the two BCMA CAR-T products and a material distinction for centers without robust outpatient neurology infrastructure.

Modifiers CMS + CPT verified May 2026

Modifiers rarely apply to Q2055 itself

Unlike weight-based drug J-codes, the single-dose Q2055 code does not generate JW (drug waste) or JZ (no-waste single-dose container) reporting in most circumstances. The cellular product is one patient-specific therapeutic dose - it is either administered in its entirety to the labeled patient or the manufacturing fails and the product is not infused (in which case Q2055 is not billed). There is no partial-vial waste scenario analogous to small-molecule oncology drugs.

Modifier 25 - same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as a CAR-T-related procedure. Pre-infusion clinical assessment is bundled; a same-day workup for a new complication is separately reportable with 25.

340B modifiers (JG, TB)

Most CAR-T treatment centers are 340B-covered entities. For 340B-acquired Q2055, follow your MAC's current 340B modifier policy (JG or TB as required). BMS CAR-T 340B and OPPS/IPPS payment interaction is jurisdiction-specific - verify with your 340B compliance team.

Modifiers on lymphodepletion (Stage 3)

Lymphodepletion uses standard chemotherapy modifier rules - JW on partial-vial waste for fludarabine and cyclophosphamide as needed; JZ when no waste. These follow the standard J9185 and J9070 modifier logic and are unrelated to Q2055 billing.

ICD-10-CM & ICD-10-PCS coding FY2026 verified May 2026

Two coding systems matter: ICD-10-CM for diagnosis (every claim), ICD-10-PCS for the CAR-T procedure (inpatient only - drives MS-DRG 018). Abecma does NOT use the Parkinsonism G20.A1/A2 codes that appear on Carvykti claims.

ICD-10-CM diagnoses

ICD-10-PCS procedures (inpatient claims)

Site of care, place of service & DRG/APC mapping FY 2026 IPPS/OPPS verified May 2026

Abecma is predominantly inpatient under MS-DRG 018; outpatient pathway is emerging at experienced cellular therapy centers. No extended outpatient surveillance encounters (that is Carvykti-specific).

MS-DRG 018 details

Effective FY 2021, CMS introduced MS-DRG 018 - "Chimeric Antigen Receptor (CAR) T-cell Immunotherapy" as a dedicated CAR-T DRG. Before FY 2021, CAR-T admissions defaulted to MS-DRG 016 (Autologous Bone Marrow Transplant w/ CC/MCC) which significantly under-reimbursed the cellular product cost. MS-DRG 018 is assigned when the ICD-10-PCS principal procedure is XW033C3, XW043C3, or a related new-technology code for autologous CAR-T administration. The relative weight for MS-DRG 018 is among the highest in the IPPS to reflect the high cell product acquisition cost. For Abecma inpatient admissions, the length of stay is typically in line with CD19 CAR-T products because of the moderate CRS rate (~85% any-grade) and well-characterized post-infusion course.

Outpatient CAR-T - APC payment

CMS established a CAR-T outpatient APC pathway; the specific APC number is updated annually in the OPPS Final Rule (APC 9248 has been used historically; verify the current rule). Outpatient billing reports Q2055 as a separately payable line item plus the 0537T-0541T administration set. If CRS develops within 7-30 days, admit to inpatient under a CRS-driven DRG (not back into MS-DRG 018).

Claim form field mapping - 4 claims, one encounter BMS + CMS verified May 2026

The Abecma encounter spans 4 separate index claims. There is no extended-surveillance claim tail (unlike Carvykti).

Claim A — Apheresis (Stage 1)

Claim B — Lymphodepletion (Stage 3)

Claim C — CAR-T infusion (Stage 4)

Claim D — CRS / ICANS readmission (Stage 5, if applicable)

Payer policy snapshot Reviewed May 2026

All major payers require PA, FACT documentation, ABECMA REMS enrollment confirmation, and indication-specific eligibility documentation. No neurological monitoring plan required (that is Carvykti-specific).

NCCN Guidelines

NCCN Multiple Myeloma Guidelines (current version) list Abecma as Category 1 at 2L+ in triple-class-exposed disease (KarMMa-3) and at 4L+ in patients exposed to PI + IMiD + anti-CD38 mAb (KarMMa). NCCN compendium support strengthens coverage arguments, particularly for 2L+ Abecma following the April 2024 FDA approval.

Required PA documentation checklist

• FACT (or FACT-JACIE) accreditation certificate for the treatment center
• ABECMA REMS certification letter for the prescribing physician and the facility (NOT the Carvykti REMS letter, NOT Breyanzi/Yescarta/Tecartus REMS — manufacturer- and product-specific certifications are independent)
• Prior therapy log: each regimen, dates, IMWG response, reason for discontinuation
• Indication-specific gate documentation:
  • 2L+ MM (KarMMa-3): explicit triple-class exposure — prior IMiD + prior PI + prior anti-CD38 mAb (with at least 2 prior lines)
  • 4L+ MM (KarMMa): ≥4 prior lines including PI + IMiD + anti-CD38 mAb
• ECOG performance status (most policies require 0-2)
• Diagnostic pathology / flow cytometry / serum protein electrophoresis confirming BCMA-expressing myeloma
• Imaging / disease burden assessment within recent window (per payer policy, often 30-60 days)
• Cardiac and pulmonary clearance (LVEF, pulmonary function tests as required)
• Absence of active autoimmune disease requiring systemic immunosuppression

Medicare reimbursement CMS Q2 2026 (live)

Q2055 has a quarterly ASP payment limit; MS-DRG 018 sets the inpatient DRG payment; OPPS APC handles outpatient (uncommon for Abecma but emerging).

MS-DRG 018 inpatient payment

Inpatient Abecma claims default to MS-DRG 018 (Chimeric Antigen Receptor Immunotherapy). The DRG relative weight is set annually in the IPPS Final Rule to reflect the high cellular product acquisition cost. MS-DRG 018 bundles the Q2055 drug acquisition into the DRG payment; line-item Q2055 billing on the inpatient claim is informational, not separately payable. Outlier payment may apply when actual costs significantly exceed the DRG payment.

NTAP status (FY 2026)

Abecma received CMS New Technology Add-on Payment (NTAP) status after the March 2021 FDA approval. The standard NTAP window is three years post-approval, so the original Abecma NTAP expired in 2024. The April 2024 KarMMa-3 2L+ approval did not reset the NTAP clock for the same product. Verify the current FY 2026 IPPS Final Rule for any residual Abecma NTAP status before assuming any add-on payment applies. In most current claim cycles, MS-DRG 018 base payment (plus outlier as applicable) is the operative Medicare inpatient payment mechanism for Abecma.

OPPS / APC outpatient payment

When Abecma is administered outpatient (uncommon but emerging), CMS pays under the OPPS CAR-T APC pathway with Q2055 as a separately payable line item plus the 0537T-0541T administration set. Verify the current OPPS Final Rule Addendum B for the assigned APC and payment rate.

Patient assistance — BMS Cell Therapy 360 BMS verified May 2026

BMS administers Abecma patient support through BMS Cell Therapy 360, the joint hub for Abecma and Breyanzi cellular therapies.

• BMS Cell Therapy 360 — benefits investigation, PA support, appeals, case management, and copay assistance for commercially insured patients. Same hub as Breyanzi — case managers cover both BMS CAR-T products. Phone-based access; case managers assigned per patient.
• BMS Patient Assistance Foundation — free product for eligible uninsured / underinsured patients meeting income criteria. Application via BMS Cell Therapy 360.
• Independent foundations: PAN Foundation, HealthWell Foundation, Leukemia & Lymphoma Society Co-Pay Assistance — multiple myeloma funds open quarterly; check current status before referral.
• Travel grants: BMS Cell Therapy 360 provides travel assistance for patients > 50-100 miles from an ABECMA-certified FACT center. International Myeloma Foundation also offers travel grants.
• Medicare patients: BMS Cell Therapy 360 provides Medicare navigation but cannot directly subsidize Medicare cost-share per anti-kickback rules. Refer Medicare patients to PAN, HealthWell, and LLS multiple myeloma funds.

Common denial reasons & appeal logic Reviewed May 2026

Abecma denial patterns reflect the REMS structure, triple-class-exposure gate, and Abecma/Carvykti Q-code disambiguation.

Abecma billing FAQ Reviewed May 2026

Is Abecma a CD19 CAR-T?

No. Abecma is an anti-BCMA CAR-T, not a CD19 CAR-T. BCMA (B-cell maturation antigen) is expressed on plasma cells and myeloma cells; CD19 is expressed on B lymphocytes and most B-cell lymphomas/leukemias. Abecma is approved exclusively for multiple myeloma. Do not confuse Q2055 (Abecma, BCMA, myeloma) with the CD19 CAR-T Q-codes (Q2041 Yescarta, Q2042 Kymriah, Q2053 Tecartus, Q2054 Breyanzi) used for B-cell lymphoma and ALL. Abecma was, in fact, the FIRST CAR-T approved for multiple myeloma (March 26, 2021), establishing the BCMA CAR-T category.

What is the difference between Q2055 (Abecma) and Q2056 (Carvykti)?

Both are BCMA-directed CAR-T products approved for R/R multiple myeloma, but they have separate Q-codes, separate REMS programs, and clinically distinct features. Abecma (Q2055) uses a conventional single BCMA-binding domain and was the FIRST CAR-T approved for myeloma (March 2021, KarMMa); 2L+ approval via KarMMa-3 in April 2024 requires triple-class exposure. Carvykti (Q2056) uses a dual BCMA-binding-domain construct (two camelid VHH domains on one CAR) and was approved later (February 2022, CARTITUDE-1); 2L+ approval via CARTITUDE-4 in April 2024 requires lenalidomide-refractory disease (a different gate). Carvykti carries the unique Parkinsonism/MNT delayed toxicity that Abecma does not. The chain-of-identity label is the authoritative source for which Q-code to bill.

Does Abecma have a Parkinsonism / MNT toxicity warning?

No. The delayed Parkinsonism and movement / neurocognitive toxicity (MNT) signal is a Carvykti-specific phenomenon that emerged in CARTITUDE-1 and drove the Carvykti boxed warning. Abecma's pivotal trials (KarMMa, KarMMa-3) did not surface that signal, and the ABECMA boxed warning is limited to CRS, ICANS, HLH/MAS, prolonged cytopenia, and secondary hematological malignancies (including T-cell malignancies per the FDA class-wide CAR-T update, 2024). The ABECMA REMS does NOT require extended neurological monitoring through 1 year post-infusion. Standard 30-day post-infusion CAR-T monitoring applies, consistent with CD19 CAR-T products.

What is the Q2055 ASP and how often does it update?

Q2055 has a Medicare ASP+6% payment limit published quarterly by CMS. The Q2 2026 payment limit is $559,781.081 per single dose. ASP files update at the start of each calendar quarter (Q1, Q2, Q3, Q4). Always verify against the live CMS ASP pricing file (medicare-asp.js on this page is live-bound) before finalizing payer estimates or shifting site-of-service decisions on margin.

Can Abecma be administered outpatient?

Outpatient pathway is policy-emerging for Abecma. Outpatient share is estimated at ~10-20% at qualifying centers (higher than Carvykti's single-digit share, lower than Breyanzi's ~30-50% share). The CRS rate (~85% any-grade, ~5% Grade 3+) is moderate, and the lack of extended Parkinsonism/MNT monitoring complexity makes outpatient operationally simpler than for Carvykti. Verify the payer-specific site-of-service policy before assuming outpatient is approved; most cases still default inpatient under MS-DRG 018.

Does Abecma require BMS Cell Therapy 360 enrollment?

BMS Cell Therapy 360 enrollment is not a strict REMS requirement, but operationally every Abecma case engages Cell Therapy 360 for benefits investigation, PA support, copay assistance (commercial only), travel grants, and case management. Cell Therapy 360 case managers have direct lines into the ABECMA REMS team and payer escalation queues. Engage Cell Therapy 360 at the apheresis-scheduling step, not after PA denial. Note: BMS Cell Therapy 360 also handles Breyanzi, so a single case manager at the center may cover both products.

What if Q2055 manufacturing fails?

If BMS / 2seventy bio cannot deliver a successful Abecma product (manufacturing failure rate has historically been low single-digit percent), do not bill Q2055. Bill the apheresis (Claim A) and any lymphodepletion (Claim B) as rendered. Document the manufacturing non-conformance report from BMS in the chart. Some payers allow repeat apheresis under separate authorization; verify before scheduling.

Abecma was first — does that affect coverage?

Abecma's historical role as the first CAR-T approved for multiple myeloma (March 2021) means most payer policies have ~4 years of operational experience with Abecma adjudication. PA templates, prior-line documentation expectations, and REMS verification workflows are well-established. This can be a comparative advantage versus newer products: appeals teams at major payers tend to have institutional knowledge of Abecma cases, which can simplify escalation. The 2L+ KarMMa-3 approval is more recent (April 2024) and may require explicit citation in PA narratives for plans that have not yet updated their CAR-T policy templates.

Source documents Verified May 2026

• FDA Abecma Prescribing Information (idecabtagene vicleucel) — BLA 125736, original approval Mar 26, 2021 (KarMMa, 4L+ MM — FIRST CAR-T approved for multiple myeloma); 2L+ MM approval Apr 4, 2024 (KarMMa-3). DailyMed setid b90c1fe7-f5cc-464e-958a-af36e9c26d7c. Most recent label revision: November 25, 2025 (boxed warning includes T-cell malignancies under Secondary Hematological Malignancies, per FDA class-wide CAR-T update 2024).
• CMS Q2 2026 ASP Pricing File — Q2055 payment limit $559,781.081 per single dose (live-bound on this page).Updated quarterly.
• FY 2026 IPPS Final Rule — MS-DRG 018 (Chimeric Antigen Receptor Immunotherapy), NTAP determinations for CAR-T products. CMS Federal Register publication.
• CY 2026 OPPS Final Rule — CAR-T APC pathway (APC 9248 historically); Addendum B per quarter.
• NCD 110.24 (CAR-T Cell Therapy) — National Coverage Determination, covers FDA-approved autologous CAR-T including both Abecma indications.
• NCCN Multiple Myeloma Clinical Practice Guidelines — Abecma listed Category 1 at 2L+ (post-triple-class exposure, KarMMa-3) and Category 1 at 4L+ (post-PI/IMiD/anti-CD38, KarMMa).
• KarMMa — Munshi NC et al., "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma," NEJM 2021; 384:705-716. DOI 10.1056/NEJMoa2024850. The pivotal trial establishing Abecma as the first CAR-T for multiple myeloma.
• KarMMa-3 — Rodriguez-Otero P et al., "Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma," NEJM 2023; 388:1002-1014. DOI 10.1056/NEJMoa2213614.
• BMS Abecma product site — abecma.com (patient site); BMS Cell Therapy 360 hub.
• FACT Standards for Cellular Therapy — FACT-JACIE Standards, current revision; factwebsite.org.
• ABECMA REMS — BMS-administered REMS program; current REMS document at the BMS Abecma HCP portal. Administered through BMS Cell Therapy 360.
• BMS Cell Therapy 360 — patient hub for Abecma and Breyanzi cellular therapies; benefits investigation, PA, copay (commercial), travel.
• BMS Patient Assistance Foundation — free product for eligible uninsured / underinsured patients.
• AMA CPT 2026 — Category III codes 0537T-0541T for CAR-T administration; CPT 38206 for autologous leukapheresis.
• IMWG Response Criteria for Multiple Myeloma — for documentation of triple-class exposure status and prior-line responses in PA narratives.